Your search
Results 167 resources
-
Summary. Blog post on replicable data science to tackle corruption.
-
Summary. Advocates are arguing that the Thirteenth Amendment prohibits usurious loans. An invitation to reframe unregulated consumer loans as a matter of rights.
-
Summary. Recent work has offered competing explanations for the long-term evolution of corporate political action in the United States. In one, scholars have
-
Summary. A decade after Congress gave the F.D.A. the power to regulate tobacco products like e-cigarettes, the federal government has repeatedly delayed or weakened efforts that could have protected teenagers.
-
Summary. Includes discussion of the limited utility of transparency for checking legal/institutional corruption.
-
Summary. Describes culpable behavior by opioid companies and the prospects for litigation to address it.
-
Summary. Describes how commonly drug companies fail to adhere to obligations to disclose clinical trial results and how commonly they are willing to share clinical trial data. My collaboration with Dr. Miller is a direct result of my Safra fellowship.
-
Summary. Juul is giving Meharry Medical College, a historically black institution, money for a research center that will study, among other things, Juul.
-
Summary. Juul needs good science to prove to the F.D.A. that its e-cigarettes offer more benefits than risks. Some researchers say they are loath to take the company’s money.
-
Summary. But it will only work if it takes a cue from the successful Democracy Voucher Program in Seattle
-
Summary. This piece argues that, by framing individuals as the source of public health problems, nudging tends to serve the commercial interests of powerful corporate actors.
-
Summary. Juul has told the F.D.A. it will do all it can to stop youth vaping. But in state capitols and city halls around the country, the company is embracing measures that undermine that vow.
-
Summary. Describes how publicly disclosing drug company payments to physicians affects trust.
-
Summary. This essay outlines the webs of close relationships that opioid companies created with doctors, professional associations, universities, academic medical centers, and public health NGOs. The essay argues that these relationships exacerbated the opioid crisis.
Explore
Resource type
- Blog Post (7)
- Book (2)
- Book Section (5)
- Interview (2)
- Journal Article (103)
- Newspaper Article (8)
- Presentation (1)
- Report (12)
- Web Page (27)